拟诊早期非小细胞肺癌患者接受立体定向体部放疗期间循环肿瘤细胞评估:一项前瞻性先导研究
这项前瞻性先导研究纳入48例临床诊断I期NSCLC并接受SBRT的患者,用腺病毒探针检测循环肿瘤细胞(CTC)。42%的患者放疗前CTC阳性,放疗后1个月和3个月CTC计数下降;3例进展患者均有≥1次放疗后CTC阳性,早于临床进展中位16个月。作者认为CTC监测可能提前提示复发或进展,阴性结果可能提供疾病控制的 reassurance。
要点
- 48例拟诊早期NSCLC接受SBRT,42%放疗前CTC阳性,中位计数4.2个/mL。
- 放疗后1个月和3个月CTC中位计数分别降至0.2和0.6个/mL。
- 3例进展患者放疗后CTC阳性早于临床进展中位16个月。
核心结论
- SBRT后CTC监测可能提前提示拟诊早期NSCLC的复发或进展。
- 治疗后CTC阴性可能提供疾病控制的 reassurance。
- CTC分析可能有助于增强该人群的临床诊断和随访。
研究设计与样本
- 机构审查委员会批准的前瞻性临床试验,纳入临床诊断I期NSCLC并接受SBRT的患者。
- 连续纳入48例患者,T1a占73%、T1b占21%、T2a占6%。
- 外周血通过表达绿色荧光蛋白的腺病毒探针检测CTC,CTC阳性定义为每mL采集血1.3个绿色荧光蛋白阳性细胞。
- SBRT分割≤5次,中位剂量50 Gy分12.5 Gy/次,所有病例生物等效剂量≥100 Gy。
- 放疗前、放疗期间及放疗后(1、3、6、12、18、24个月)采集样本,中位随访14.2个月。
主要发现
- 20例(42%)放疗前CTC阳性,中位CTC计数4.2个/mL(IQR 2.2-18.7)。
- 这20例中17例有可评估的放疗后CTC,1个月中位计数0.2(IQR 0.1-0.8)、3个月中位计数0.6(IQR 0-1.1),均较放疗前下降。
- 这17例中3例出现疾病进展,中位时间19.9个月;3例均有≥1次放疗后CTC阳性,早于临床进展中位16个月(范围2-17个月)。
- 放疗前CTC可检测且所有放疗后CTC均阴性的患者中,无复发或进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In patients treated with stereotactic body radiation therapy (SBRT) for presumed early stage non-small cell lung cancer (NSCLC), detection and monitoring of circulating tumor cells (CTCs) may be useful for assessing treatment response safely and noninvasively. No published reports of CTC trends in this patient population exist to date. METHODS AND MATERIALS: Patients with clinically diagnosed stage I NSCLC treated with SBRT were eligible for this institutional review board-approved prospective clinical trial. Peripheral blood samples were assayed for CTCs via a green fluorescent protein-expressing adenoviral probe. CTC positivity was defined as 1.3 green fluorescent protein-positive cells/mL of collected blood. Samples were obtained before (pre-radiation therapy [RT]), during, and after SBRT (post-RT; months 1, 3, 6, 12, 18, and 24). SBRT was delivered in ≤5 fractions (median dose of 50 Gy in 12.5 Gy fractions) to a biological equivalent dose of ≥100 Gy in all cases. RESULTS: Forty-eight consecutive patients (T1a [73%], T1b [21%], and T2a [6%]) were enrolled. Median follow-up was 14.2 months. Twenty patients (42%) had a positive CTC level pre-RT, with a median CTC count of 4.2 CTCs per mL (interquartile range [IQR], 2.2-18.7). Of these 20 patients, 17 had evaluable post-RT CTC evaluations showing reduced CTC counts at 1 month (median, 0.2; IQR, 0.1-0.8) and 3 months (median, 0.6; IQR, 0-1.1). Three of these 17 patients experienced disease progression at a median of 19.9 months; all 3 experienced ≥1 positive post-RT CTC test predating clinical progression by a median of 16 months (range, 2-17 months). In contrast, among patients presenting with CTC-detectable disease and for whom all post-RT CTC tests were negative, none experienced recurrence or progression. CONCLUSIONS: CTC monitoring after SBRT for presumed early stage NSCLC may give lead-time notice of disease recurrence or progression. Conversely, negative CTC counts after treatment may provide reassurance of disease control. CTC analysis is thus potentially useful in enhancing clinical diagnosis and follow-up in this population.
引用
- Frick MA, Kao GD, Aguarin L, et al. Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study. Int J Radiat Oncol Biol Phys. 2018. PMID: 30244877. doi:10.1016/j.ijrobp.2018.06.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。